The way you think, the way you behave, the way you eat, can influence your life by 30 to 50 years.
-Deepak Chopra
PNA Spotlight: Dr. Manish Aghi
This month the PNA Spotlight focuses on Dr. Manish K. Aghi.Dr. Manish Aghi is a neurosurgeon specializing in brain tumors at UCSF Medical Center. He cares for adult patients with a wide range of conditions, including astrocytomas and anaplastic astrocytomas, oligodendrogliomas, glioblastomas, meningiomas and pituitary adenomas. As principal investigator at the UCSF Brain Tumor Research Center, his interests include glioblastoma angiogenesis, mechanisms of glioblastoma resistance to anti-angiogenic therapy and experimental glioblastoma therapies such as cancer-killing viruses.
Professor Aghi earned his medical degree and a doctoral degree in neurosciences from Harvard Medical School. He completed a residency in neurosurgery at Massachusetts General Hospital. He is a member of the Society for Neuro-Oncology, American Association of Neurological Surgeons, Congress of Neurological Surgeons and Pituitary Network Association. Among his honors are the Preuss and Mahaley awards from the American Association of Neurological Surgeons, and the Ronald L. Bittner Award, Synthes Skull Base Award and Integra Foundation Award from the Congress of Neurological Surgeons.
His answers follow.
PNA Medical Corner: Pituitary Centers of Excellence
This month the PNA Medical Corner focuses on an article co-authored by several members and colleagues of the PNA: Drs. Chanson, Kaiser, Laws, van der Lely, and Melmed. It addresses a topic that PNA has sought to promote for decades: the designation of Pituitary Centers of Excellence, where patients can get highly specialized care
Link: https://pubmed.ncbi.nlm.nih.gov/37640885/
Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers
Featured News and Updates
The FDA has approved NGENLA (somatrogon-ghla)
The FDA has approved NGENLA (somatrogon-ghla), a once-weekly, human growth hormone analog indicated for treatment of pediatric patients aged three years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.
News Articles May 2024
Does a form of dwarfism improve cardiovascular risk?
A study in the Journal Med looks at the longevity of people with Laron’s Syndrome, who have low-growth hormone signaling that causes a form of dwarfism but may also confer lower risk of cancer and heart disease. Read more in the Daily Mail: https://tinyurl.com/5cdmafaj or consult the original study: https://tinyurl.com/2pvzzbev
Case study: Surgical Treatment of Pituitary Macroadenomas
A study published on Cureus.com looks at the case of a 48-year old woman with a pituitary macroadenoma. Surgeons removed the tumor but she suffered post-operative complications that required extensive management. They conclude that this type of surgery is complex and requires individualized care.
Acromegalic receives special-made shoes
An article on Fox5dc.com features the story of an acromegaly patient in Venezuela who holds the record for the world’s biggest feet, according to the Guinness Book of World records. The man, named Jeison Rodriguez Hernandez, has size 26 feet and gets his shoes special-made a company in Germany. Read more: https://www.fox5dc.com/news/man-with-worlds-largest-feet-receives-new-custom-shoes
Study: Female Cushing’s patients develop more new diseases than men after treatment
An article in Cushing’s Disease news looks at a study published in the journal Endocrinology, Diabetes & Metabolism. Researchers found that women were more likely to develop additional diseases than men, when in remission after treatment for Cushing’s syndrome. Read more: https://cushingsdiseasenews.com/news/more-new-disorders-women-than-men-after-cushings-remission-study/
Research Articles
May 2024 Research Articles
Pituitary Surgery
Cushing’s
Hormonal Health
Hypogonadotropic Hypogonadism.
Diagnosis and treatment of hypogonadism in men seeking to preserve fertility – what are the options?
Pituitary Tumors
Disulfiram mediated anti-tumour effect in pituitary neuroendocrine tumours by inducing cuproptosis.
A long-term prognosis study of human USP8-mutated ACTH-secreting pituitary neuroendocrine tumours.
Immune landscape and progress in immunotherapy for pituitary neuroendocrine tumors.
Copyright © 2024 Pituitary Network Association All rights reserved.
Disclaimer: PNA does not engage in the practice of medicine. It is not a medical authority, nor does it claim to have medical expertise. In all cases, PNA recommends that you consult your own physician regarding any course of treatment or medication.
Our mailing address is:
Pituitary Network Association
P.O. Box 1958
Thousand Oaks, CA 91358
(805) 499-9973 Phone - (805) 480-0633 Fax
Email info@pituitary.org
You are receiving this Newsletter because you have shown interest in receiving information about our activities.
If you do not want to receive any more emails from PNA, Unsubscribe.
